Suppr超能文献

[天然及合成亲水性聚合物在不同释放曲线盐酸二甲双胍片制剂中的应用]

[The use of natural and synthetic hydrophilic polymers in the formulation of metformin hydrochloride tablets with different profile release].

作者信息

Kołodziejczyk Michał Krzysztof, Kołodziejska Justyna, Zgoda Marian Mikołaj

机构信息

Zakład Technologii Postaci Leku, Katedra Farmacji Stosowanej, Uniwersytet Medyczny w Łodzi.

出版信息

Polim Med. 2012;42(3-4):167-84.

Abstract

AIM OF STUDY

Metformin hydrochloride after buformin and phenformin belongs to the group of biguanid derivatives used as oral anti-diabetic drugs. The object of the study is the technological analysis and the potential effect of biodegradable macromolecular polymers on the technological and therapeutic parameters of oral anti-diabetic medicinal products with metformin hydrochloride: Siofor, Formetic, Glucophage, Metformax in doses of 500mg and 1000mg and Glucophage XR in a dose of 500 mg of modified release.

MATERIALS AND METHODS

Market therapeutic products containing 500 and 1000 mg of metformin hydrochloride in a normal formulation and 500 mg of metformin hydrochloride in a formulation of modified release were analyzed. Following research methods were used: technological analysis of tablets, study of disintegration time of tablets, evaluation of pharmaceutical availability of metformin hydrochloride from tested therapeutic products, mathematical and kinetic analysis of release profiles of metformin hydrochloride, statistical analysis of mean differences of release coefficients.

RESULTS

The percentage of excipients in the XR formulation is higher and constitutes 50.5% of a tablet mass. However, in standard formulations the percentage is lower, between 5.5% and 12.76%. On the basis of the results of disintegration time studies, the analysed therapeutic products can be divided into two groups, regardless the dose. The first one are preparations with faster (not fast!) disintegration: Glucophage i Metformax. The second group are preparations with slower disintegration, more balanced in the aspect of a high dose of the biologically active substance: Formetic and Siofor. Products with a lower content of excipients (Metformax, Glucophage) disintegrate in a faster way. The disintegration rate of the products with a higher content of excipients (Formetic, Siofor) is slower. The appearance of metformin hydrochloride concentration in the gastrointestinal contents, balanced in time, caused by a slower disintegration-dissolving of a tablet, is conducive to the reduction of gastrointestinal side effects and better tolerance of the therapeutic product by a patient. The study on pharmaceutical availability indicated relevant kinetic differences between tested therapeutic products. They are particularly visible between standard formulations and the one with prolonged release (Glucophage XR500). Its release profile bears features of kinetics similar to zero-order reactions.

CONCLUSIONS

Tested therapeutic products contain a large amount of the biologically active substance in relation to the content of excipients. A higher content of excipients in a single tablet mass distinguishes Siofor in comparison with Glucophage i Metformax. The excipients used in the formulations of tested preparations are comparable. A higher percentage of binding agents (HPMC, PVP) is observed, but there is a lack of typical disintegrants which results in a longer disintegration time up to 15 minutes. Siofor disintegrates at the same time as Formetic, but longer than Glucophage i Metformax. Considering the large content of the active substance and pharmacological properties of metformin hydrochloride, such a disintegration might have beneficial consequences, because the amount of the free active substance in the gastrointestinal tract will increase over the longer time period what will reduce the level of gastrointestinal side effects. The release profiles of metformin hydrochloride from tested therapeutic products are comparable. The Glucophage XR 500 formulation with the release kinetics of metformin hydrochloride similar to the zero-order kinetics is completely different from the others. The above is confirmed by the mathematical analysis of release profiles of metformin hydrochloride from tested preparations where equations of lines describing the release profile are characterized by similar values of correlation coefficients.

摘要

研究目的

盐酸二甲双胍继丁双胍和苯乙双胍之后,属于用作口服抗糖尿病药物的双胍衍生物类。本研究的对象是可生物降解高分子聚合物对含盐酸二甲双胍的口服抗糖尿病药品(500毫克和1000毫克剂量的Siofor、Formetic、Glucophage、Metformax以及500毫克缓释剂量的Glucophage XR)的工艺和治疗参数的工艺分析及潜在影响。

材料与方法

分析了市售的普通制剂中含500毫克和1000毫克盐酸二甲双胍以及缓释制剂中含500毫克盐酸二甲双胍的治疗产品。采用了以下研究方法:片剂的工艺分析、片剂崩解时间的研究、受试治疗产品中盐酸二甲双胍的药物可利用度评估、盐酸二甲双胍释放曲线的数学和动力学分析、释放系数平均差异的统计分析。

结果

缓释制剂中辅料的百分比更高,占片剂质量的50.5%。然而,在标准制剂中该百分比更低,在5.5%至12.76%之间。基于崩解时间研究的结果,无论剂量如何,所分析的治疗产品可分为两组。第一组是崩解较快(不是快速!)的制剂:Glucophage和Metformax。第二组是崩解较慢的制剂,在高剂量生物活性物质方面更为平衡:Formetic和Siofor。辅料含量较低的产品(Metformax、Glucophage)崩解更快。辅料含量较高的产品(Formetic、Siofor)的崩解速率较慢。片剂较慢的崩解 - 溶解导致胃肠道内容物中盐酸二甲双胍浓度随时间平衡出现,这有利于减少胃肠道副作用并使患者对治疗产品有更好的耐受性。药物可利用度研究表明受试治疗产品之间存在相关的动力学差异。它们在标准制剂和缓释制剂(Glucophage XR500)之间尤为明显。其释放曲线具有类似于零级反应的动力学特征。

结论

受试治疗产品相对于辅料含量含有大量生物活性物质。与Glucophage和Metformax相比,Siofor的单片辅料含量更高。受试制剂配方中使用的辅料具有可比性。观察到粘合剂(羟丙基甲基纤维素、聚乙烯吡咯烷酮)的百分比更高,但缺乏典型的崩解剂,这导致崩解时间长达15分钟。Siofor与Formetic同时崩解,但比Glucophage和Metformax崩解时间长。考虑到活性物质的大量含量和盐酸二甲双胍的药理特性,这样的崩解可能会产生有益的结果,因为胃肠道中游离活性物质的量将在更长时间段内增加,这将降低胃肠道副作用的水平。受试治疗产品中盐酸二甲双胍的释放曲线具有可比性。盐酸二甲双胍释放动力学类似于零级动力学的Glucophage XR 500制剂与其他制剂完全不同。从受试制剂中盐酸二甲双胍释放曲线的数学分析证实了上述情况,其中描述释放曲线的直线方程具有相似的相关系数值。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验